©2025 Stanford Medicine
Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery
Not Recruiting
Trial ID: NCT01245595
Purpose
Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. We currently have few medications to prevent this kidney injury. The hypothesis of this study is that giving aminophylline after heart surgery can decrease the acute kidney injury.
Official Title
A Randomized Placebo Controlled Trial of Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery With Cardiopulmonary Bypass
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
* Less than 18 years old, undergoing cardiac surgery with bypass
* neonates must be at least 36 weeks gestational age
Exclusion Criteria:
* History of arrythmia or seizure, on extracorporeal membrane oxygenation (ECMO) support, already taking aminophylline/theophylline, liver failure, sepsis, on renal replacement therapy
Intervention(s):
drug: Aminophylline
drug: Placebo
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
David M Axelrod, MD